Data-driven CRB report reveals critical insights on what companies manufacturing novel therapies need to keep pace with today's unprecedented rate of discovery and innovation
KANSAS CITY, Mo., Sept. 27, 2022 /PRNewswire/ -- From novel cell therapies to innovative RNA treatments, one thing is certain: The world is entering a new era defined by innovation and therapy breakthroughs, when patients need them the most. A groundbreaking new report from CRB ? a leading provider of sustainable engineering, architecture, construction, and consulting solutions to the life sciences industry ? reveals the challenges facing manufacturers and how they can keep pace with this new rate of discovery.
Launching today, CRB's new Horizons: Life Sciences report finds a rapidly maturing life sciences industry chasing more: more diversification, more multimodal and nimble development processes, more partnership, and more talent.
The report features perspectives from nearly 500 industry leaders representing North American, European, and multinational companies, primarily from R&D roles upstream of GMP manufacturing. The new report finds that companies are investing in novel research, pushing beyond traditional comfort zones, and moving cautiously but unwaveringly toward an advanced standard of care for critically ill patients.
"While the COVID-19 pandemic taught us new lessons about the quick and safe delivery of critical vaccines, the learnings from that global shock are only now being understood," writes Tim Barba, CRB's Chief Operating Officer for Global Technical Operations, in the report's opening passages. "They guide our thinking about highly adaptable research and production environments. They inform our collaboration with industry and trade partners in the pursuit of cures. They even teach us to focus inward to make sure our researchers, support teams and staff have the right tools, technology, and high-level support required to get the job done."
Available as a free download, the report's eight chapters analyze the nuances driving today's trends and their impact on submarkets within life sciences. Each provides a contextualized view based on the Horizons survey data of what companies are doing to drive success -- from the lab through manufacturing, and at every point between.
The Horizons: Life Sciences report is the third in a series of CRB's survey-based Horizons explorations of critical trends in the life sciences industry. See previous Horizons reports here.
CRB is a leading provider of sustainable engineering, architecture, construction, and consulting solutions to the food and beverage and life sciences industries. Led by its innovative ONEsolutiontm service, CRB provides successful integrated project delivery for clients demanding high-quality solutions, on time and within budget. The company's nearly 1,800 employees provide world-class solutions that drive success and positive change for clients, people, and communities. CRB is a privately held company with a rich history of serving clients throughout the world, consistently striving for the highest standard of technical knowledge, creativity, and execution.
These press releases may also interest you